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ANALISIS RESEPTOR VEGF DAN KEPADATAN MIKROVASKULAR 
YANG DIINDUKSI MENGGUNAKAN NMU DI BAWAH PENGARUH 
PLATELET FACTOR 4 DAN RAPAMYCIN 
ABSTRAK 
 
Kanser payu dara merupakan pembunuh utama wanita diseluruh dunia dan 
merupakan kanser penyebab kematian kedua tertinggi di United States.  
Angiogenesis merupakan pembentukan salur darah baru daripada salur darah utama 
yang merupakan proses yang normal dan sangat penting untuk pembesaran dan 
pertumbuhan serta proses pemulihan dan proses pembentukan tisu bergranul. 
Angiogenesis memainkan peranan yang penting dalam membekalkan nutrien dan 
oksigen kepada perkembangan sel dan juga berperanan sebagai laluan bagi 
metastasis tumor.  Pada masa kini, ramai penyelidik sedang menjalankan 
penyelidikan yang teliti dalam bidang ini yang menjurus ke arah menyekat 
perkembangan tumor melalui sekatan ke atas proses angiogenesis. Dalam kajian ini, 
N-nitroso-N-methylurea (NMU) telah diaruh bagi menyebabkan karsinoma kalenjar 
mamari yang teruk dan dirawat dengan menggunakan dadah anti-angiogenik 
termasuklah rapamycin iaitu sejenis perencat imun yang berkesan dan Platelet Factor 
4 (PF4) iaitu sejenis pengekang angiogenik yang disuntik secara berasingan atau 
secara kombinasi bagi menentukan tahap keberkesanan sebagai anti-kanser dan anti-
angiogenik. Flt-1, Flk-1 and Flt-4 telah dipilih sebagai penanda yang mewakili 
proses angiogenesis, pembezaan, pembahagian sel dan penelapan vaskular kanser 
manakala CD34 telah dipilih untuk penakrifan kepadatan mikrovaskular di dalam 
model NMU. Ekspresi keseluruhan penanda ini samada dalam bentuk gen dan protin 
xxiv 
 
telah dianalisis menggunakan kaedah immunohistokimia dan asai Real-Time-PCR. 
Penemuan daripada kumpulan yang tidak dirawat menunjukkan bahawa darjah 
penerukan malignan meningkat secara signifikan seiring dengan pertumbuhan kanser 
payudara tersebut. Penemuan kanser yang terbentuk pada kumpulan tidak terawat 
menunjukkan keterukan keadaan malignan didorong oleh pembentukan tumor 
mamari. Pembentukan kanser yang kurang agresif secara pengkelasan histologi 
sebagai Invasive Ductal Carcinoma (IDC)-Cribiform yang mana banyak dijumpai di 
dalam tisu kanser bersaiz kecil. Sebaliknya, perkembangan lesi yang lebih teruk yang 
diklasifikasikan secara histologi sebagai IDC-papilari dan “Not Otherwise Specified” 
(NOS) telah dijumpai pada tumor yang besar. Sementara itu, analisis di dalam 
kumpulan yang terawat menunjukkan rawatan menggunakan rapamycin berjaya 
merencat pertumbuhan kanser payudara dan angiogenesis secara signifikan pada 
peringkat protein dan gen. Semua ekspresi penanda reseptor signal menunjukkan 
penindasan signifikan yang dikaitan dengan perencatan terhadap tumor. Sebaliknya, 
rawatan dengan PF4 telah menunjukkan kurang keberkesanan dalam penyekatan 
angiogenesis tumor yang dicerminkan daripada penindasan ekspresi Flt-1, Flk-1 and 
Flt-4yang tidak signifikan. Hampir menyerupai rawatan menggunakan rapamycin, 
kombinasi rawatan menggunakan rapamycin dan PF4 telah menunjukkan penindasan 
ekspresi Flt-1, Flk-1 dan Flt-4 di peringkat protein dan gen tetapi tidak menunjukkan 
aktiviti perencatan berganda. Pengiraan kepadatan mikrovaskular telah mendedahkan 
hubungan diantara kehadiran kapilari dan ekspresi reseptor protein signal VEGF. 
Kurang kapilari dijumpai pada tumor yang kurang agresif manakala sebaliknya pada 
tumor yang lebih agresif. Justeru itu, kajian ini mencadangkan bahawa rapamycin 
bukanlah penggalak atau sinergi dengan PF4. Malahan, PF4 mungkin bertindak 
sebagai antagonis terhadap aktiviti anti-kanser serta anti-angiogenesis bagi 
xxv 
 
rapamycin. Kesimpulannya, rapamycin adalah agen anti-angiogenik yang berkesan 
bagi kanser payudara yang dirangsang oleh NMU di dalam model tikus dan 
berpotensi digunakan sebagai rawatan untuk kanser payudara peringkat teruk. 
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ANALYSIS OF VEGF RECEPTORS AND MICROVESSEL DENSITY IN 
NMU-INDUCED BREAST CANCER UNDER THE INFLUENCE OF 
PLATELET FACTOR 4 AND RAPAMYCIN 
ABSTRACT 
 
Breast cancer is the main killer disease among women worldwide and the second 
most common cause of cancer death in women in the United States. Angiogenesis is 
the formation of a new vascular network from the pre-existing vessels. It is a normal 
and vital process for growth and development as well as in wound healing and in the 
formation of granulation tissue. Neovasculation or angiogenesis play a pivotal role in 
the supply of essential nutrients and oxygen for cell growth and also providing 
passageway for tumour metastasis. Currently, angiogenesis is being intensively 
studied to inhibit tumour progression by blocking the process. In this study, the rats 
model were induced N-nitroso-N-methylurea (NMU) to cause invasive mammary 
tumourigenesis. The rats were divided into 4 groups based on treatment given; 
rapamycin, PF4 and drug combination. The rapamycin and PF4 were administered as 
single agent or in combination to determine the anti-tumour and anti-angiogenic 
effects as well as to evaluate their nature when combined. Flt-1, Flk-1, and Flt-4 
were selected as markers for downstream mediators which represent the process of 
tumour angiogenesis, differentiation, cell proliferation and vascular permeability of 
NMU-model while CD34 marker had been selected for microvessel density (MVD) 
counting. The protein expressions and gene expression of these markers were 
evaluated using immunohistochemistry analysis and Real-time PCR assay. Findings 
from the control group had demonstrated that the severity of malignancy 
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significantly increased with the progression of the mammary tumour. Development 
of less-aggressive lesion that was histologically classified as Invasive Ductal 
Carcinoma (IDC)-Cribriform subtype was predominant in small sizes of tumour. In 
contrast, development of more-aggressive lesions that were histologically classified 
as IDC-Papillary and Not Otherwise Specified (NOS) subtypes were seen in larger 
sizes of tumour. In the treatment group, rapamycin treatment had been found to show 
significant inhibition of mammary tumour progression as well as tumour 
angiogenesis at protein and gene level. All VEGF signaling receptor markers 
expressions were significantly suppressed which were associated to significant 
tumour regression. Treatment with PF4 alone is not effective to inhibit the tumour 
angiogenesis. This was reflected in the insignificant inhibition of Flt-1, Flk-1 and Flt-
4 expression. The drug combination had obtained a significant down-regulation of 
Flt-1, Flk-1 and Flt-4 at protein and gene level but no synergistic effects were seen. 
Microvessel density counting had revealed that there is correlation (p<0.01) between 
the existing of capillary and the expression of VEGF signaling molecule receptors. 
Less capillary formation was observed in less aggressive tumours while the converse 
was seen in aggressive tumours. Thus, the present findings had suggested that 
rapamycin was not synergistic or additive to PF4. In fact, PF4 might be antagonist 
towards the action of rapamycin as anti-tumour and anti-angiogenesis. Present 
findings had concluded that rapamycin is a potent anti-angiogenic agent for the 
invasive NMU-induced mammary carcinoma in the rat model and has the potential to 
be applied   clinically as an anti-angiogenic therapy for the treatment of advanced 
stages of breast cancer. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 General introduction 
Breast cancer is an uncontrolled growth of epithelial cells lining the ducts and 
lobules of the breast tissue (Guinebretiere et al., 2005; DeSantis et al., 2009; 
Bateman, 2010). This uncontrolled growth of cells growth resulted in development of 
abnormal mass of tissue known as tumour. A tumour of the breast can exist in two 
types of carcinoma which are carcinoma in situ and invasive carcinoma (Russo and 
Russo, 2000). Tumour cells are confined within ducts or lobules during the 
carcinoma in situ stage and transforms into invasive carcinoma or metastatic when 
infiltrated into surrounding tissues or into other organs, which is also known as 
malignant breast cancer (Hanby, 2005; Sontag and Axelrod, 2005; Allred and 
Medina, 2008). Invasive carcinoma is predominantly diagnosed at an advanced stage 
of breast cancer, whilst both benign and carcinoma in situ are commonly diagnosed 
at an early stage according to a range of histopathological phenotypes (Hanby, 2005).  
Signs of breast cancer may include a lump in the breast, a change in breast 
shape, dimpling of the skin, fluid coming from the nipple, or a red scaly patch of skin 
(National Cancer Registry, 2014). In those with distant spread of the disease, there 
may be swollen lymph nodes, shortness of breath, or yellow skin (Saunders, 2014). 
Breast cancer has been diagnosed as the most common cause of cancer affecting 
women and also statistically is the main killer among women worldwide, surpassing 
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cervical cancer (Parkin and Fernandez, 2006; Porter, 2009; Ferlay et al., 2010; Jemal 
et al., 2011; Pinder, 2010; Moinfar, 2007). The incidence and mortality rate of breast 
cancer have been reported to be increasing in most of Asia countries (Sim et al., 
2006; Takiar et al., 2008; Hirabayashi et al., 2009; Medina et al., 2010; Park et al., 
2011). Based on the report by the U.S. National Cancer Institute, it is estimated that 
232,670 females and 2360 males will have breast cancer in 2014 and out of this, 
40,000 females and 430 males will die from the disease (National Cancer Registry, 
2014). Similarly, the incidence of cancer in Malaysia increased from 32,000 new 
cases in 2008 to about 37,000 in 2012 which comprise of 18.1% of breast cancer 
incidence (National Cancer Registry, 2013).  
Tumour angiogenesis, which refers to the formation of a new vascular 
network out of primary vasculature (Papetti and Herman, 2002; Harper and Moses, 
2006; Otrock et al., 2007) is essential for sustaining tumour growth in breast cancer 
(Leek and Harris, 2002; Fox et al., 2007; Zelnak and O’Regan, 2007) since breast 
cancer is known as angiogenic-dependant cancer. Angiogenesis may involves blood 
capillary or/and lymphatic vessel. Angiogenesis promotes the progression of small 
localized neoplasm which later proliferates and causes the enlargement of the tumour 
with the ability to spread by metastasis (Folkman, 1995; Rayson et al., 1999; Harper 
and Moses, 2006). Pertaining to this, signalling via vascular endothelial growth 
factor receptor pathway has been implicated as the predominant pathway in 
signalling tumour angiogenesis (Hicklin and Ellis, 2005; Lohela et al., 2009). This 
includes promoting cell proliferation via the activation of protein kinase C (PKC) 
cascade (Cebe-Suarez et al., 2006; Otrock et al., 2007). 
Nowadays, there are many treatment and therapies used for cancer which 
includes amputation, radiotherapy, chemotherapy and also alternative medicine. 
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Recently, there is an increasing awareness that some cancer preventive agents may 
act by blocking the process of angiogenesis despite previous investigated 
mechanisms which directly linked them to cell proliferation and apoptosis 
(Thompson et al., 2004). Inhibition of tumour angiogenesis suppresses tumour 
growth in many experimental models (Miller, 2004; Marty and Pivot, 2008; Chen et 
al., 2011), suggesting that tumour-induced angiogenesis may be a relevant target to 
inhibit tumour progression. In this regard, the N-nitroso-N-methylurea (NMU)-
induced mammary carcinogenesis in rat has been used extensively to evaluate the 
cancer inhibitory activity of chemopreventive agents and various nutrients 
(Thompson et al., 1991; Roomi et al., 2005; Goss et al., 2011). This model is also 
ideal for the investigation of agents that may affect blood vessel formation and/or 
growth (Thompson et al., 2004).  
Rapamycin (sirolimus; Rapamune(R); Wyeth-Ayerst, PA, USA), is a bacterial 
macrolide with anti-fungal, immunosuppressant that was recently found to have anti-
tumour activity by suppressing tumour angiogenesis (Guba et al., 2002; Law, 2005). 
Rapamycin is produced by the bacterium Streptomyces hygroscopicus which was 
found in Easter Island. Rapamycin is known to target the atypical Ser/Thr kinase 
mammalian target of rapamycin (mTOR) and inhibits the translation of key mRNA 
of proteins required for cell cycle progression. The anti-proliferative actions of 
rapamycin have been demonstrated to be due to its ability to modulate critical signal 
transduction pathways that link mitogenic stimuli to the synthesis of proteins 
required for cell cycle traverse from G1 to S (Wiederrecht et al., 1995). Impressive 
anti-proliferative activity has been demonstrated following treatment of diverse types 
of experimental tumors with rapamycin (Eng et al., 1984, Muthukkumar et al., 
1995; Seufferlein and Rozengurt, 1996). However, the poor aqueous solubility and 
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chemical stability of rapamycin precluded its clinical development as an anti-cancer 
agent. Recently, a series of rapamycin analogs with improved aqueous solubility and 
stability have been synthesized and evaluated. CCI-779 (Wyeth Ayerst, PA, USA), a 
soluble ester analog of rapamycin, was selected for development as an anti-cancer 
agent based on its prominent anti-tumor profile and favourable pharmaceutical and 
toxicological characteristics in preclinical studies (Gibbons et al., 2000). 
Platelet Factor 4 (PF4) is a tetrameric, lysine rich member of CXC 
chemokines family produced almost exclusively by megakaryocytes (Poncz et al., 
1987). Under physiological conditions, only a small amount of PF4 is taken up with 
circulating platelet, therefore a bulk of PF4 protein originates in megakaryocytes 
(Guzzo et al., 1987). PF4 was originally cloned from a human erythroleukemia cell 
line and its genetic mapping and polymorphisms were discovered soon there after. 
PF4 is stored within the granules of platelets and secreted at high concentrations in 
the vicinity of injured blood vessels following platelet activation. PF4 was 
discovered to inhibit angiogenesis in 1982. By 1990, it was shown to inhibit tumors 
in mice. In 1995, PF4 was reported to bind preferentially to vascular endothelium in 
vivo and to bind selectively to regions of active angiogenesis in vivo. By 1998, PF4 
was revealed to be a marker of new vessel formation in xenografts of human breast 
cancer (Benny et al., 2008; Kolber et al., 1995).  
Since breast cancer is angiogenesis-dependant and the tumour burden has 
been indicated as a crucial problem in advanced stages of breast cancer treatment, 
evaluation on the regulation of associated angiogenic markers under tumour-
angiogenesis suppressed environment using the invasive breast cancer model is 
important in order to improve our understanding in this area. Therefore, in the 
present study, the roles of Flt-1, Flk-1 and Flt-4 as downstream mediators of 
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angiogenesis were analysed using immunohistochemistry analysis and Real-Time 
PCR assay to find the correlation between the angiogenic markers and microvessel 
density of rat’s breast tumour induced by NMU with the influenced of rapamycin and 
PF4 .  
 
1.2 Literature review  
1.2.1 Morphogenesis of normal mammary gland  
The mammary gland of breasts is a dynamic organ which undergoes 
continuous changes during pregnancy, lactation and involution (Liu et al., 2005; 
Hatsell et al., 2005). These changes are controlled under tight hormonal regulation 
(Rillema, 1994; Lamote et al., 2004). Normal mammary gland is heterogeneously 
composed of glandular and connective tissues (Guinebretiere et al., 2005). The 
glandular tissues which are generally built of ducts and lobules are essential in 
synthesizing milk production which is strictly controlled by hormones prolactin and 
somatotropin (Lamote et al., 2004; Guinebretiere et al., 2005). These glandular 
tissues are embedded in connective tissues composed of blood and lymphatic vessels, 
nerve, adipose and fibrous tissues (Russo et al., 1982; Weigelt and Bissell, 2008). 
The connective tissues are crucial in supplying nutrition and physical support 
(Guinebretiere et al., 2005). The entire morphogenesis of mammary gland comprises 
of several stages including fetal development, growth of the gland during puberty, 
development of the gland during pregnancy and lactation (Rillema, 1994). In 
humans, the development of mammary gland begins right after birth during the 
fourth week of gestation (Polyak, 2001). During this stage, only a few poorly 
branched mammary ducts are formed (Russo et al., 1982; Rillema, 1994; Polyak, 
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2001). At the onset of puberty, secretion of hormone estrogen and progesterone 
stimulate the ductules elongation and branching which takes place at the Terminal 
End Bud (TEB) (Sternlicht, 2005). The TEB, also referred as Terminal Ductal 
Lobular Unit (TDLU) is susceptible to carcinogenesis (Russo et al., 1983). During 
pregnancy, stimulation of estrogen and progesterone as well as prolactin promotes 
differentiation of existing ductules into lobules and alveoli (Horseman, 1999). Later 
during parturition, the lobuloalveolar epithelium is converted to a secretory 
phenotype which begins synthesizing milk production (Binart et al., 2000). At the 
end of lactation, involution of the lobuloalveolar system occurs in response to milk 
stasis (Horseman, 1999; Binart et al., 2000).  
 
1.2.2 Breast cancer 
1.2.2.1 Breast cancer incidence and prevalence  
According to the report compiled by the International Agency on Cancer 
Research (IACR), breast cancer has been diagnosed as the most common cause of 
cancer and is the main killer among women worldwide surpassing cervical cancer 
(Parkin and Fernandez, 2006; Porter, 2009; Ferlay et al., 2010; Jemal et al., 2011). In 
US alone, the North American Association of Central Cancer Registries (NAACCR) 
reported 192,370 of new breast cancer cases in 2009 which accounts for 27% of all 
cancer sites (Jemal et al., 2009). Meanwhile, the National Centre for Health Statistics 
reported 40,170 death cases which represent 15% of all cancer cases reported in the 
same year as represented in Figure 1.1 (Jemal et al., 2009). Interestingly, the pattern 
reported in US concurs with the latest Malaysian Cancer Statistic 2007 which 
showed 18.1% of breast cancer incidence rate occurring among Malaysian women 
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compared to other type of cancer (National Cancer Registry, 2006). The data by 
National Cancer Registry of Malaysia also mentioned that cancer had surpassed heart 
attack as the most killing disease in Malaysia for the year of 2014 and breast cancer 
had been highlighted to be the highest incidence in Malaysia for 2007 (Globocan, 
2013). In this regard, a rapid increase of breast cancer cases were detected among 
young women from different parts of Asia which generally in advanced stages 
compared to their counterpart in developed countries as shown in Figure 1.1 (Parsa et 
al., 2006; Agarwal et al., 2007; Lin et al., 2009; Leong et al., 2010). 
 
Figure 1.1 Occurrence of ten leading cancer types in United States for estimated new 
cancer cases and death for year 2009 (Jemal et al., 2009)  
8 
 
1.2.2.2 Pathogenesis of breast carcinoma  
Breast cancer arises from a series of mutations that accumulates for over 
many years (Hayat, 2002; Kwei et al., 2010). Generally, cancer cells possessed six 
essential characteristics to ensure their survival namely (1) self-sufficiency in growth 
signals, (2) resistance to growth-inhibitory signals, (3) insensitive to apoptosis, (4) 
unlimited replicative potential, (5) sustained angiogenesis and (6) tissue invasion and 
metastasis (Hanahan and Weinberg, 2000; Liu et al., 2005). One of the key hallmarks 
of breast carcinoma is the loss of the ability to control growth within organized 
bilayered ducts as shown in Figure 1.2 (Mallon et al., 2000; Guinebretiere et al., 
2005). Normal mammary ducts and alveoli consist of a single layer of epithelial cells 
lining the lumen and myoepithelial cells lining the basement membrane (Figure 
1.3(A)) (Mallon et al., 2000; Polyak, 2001; Guinebretiere et al., 2005). The close 
cellular contact of luminal and myoepithelial cells enables autocrine and paracrine 
interaction potentially mediated by chemokines either between luminal and epithelial 
cells or between luminal epithelial cells and stromal cells including fibroblast, 
adipocytes, macrophages, eosinophil granulocytes, lymphocytes and endothelial cells 
(Polyak, 2001). However, aberrant proliferation of epithelial cells and myoepithelial 
cells lead to the formation of benign lesions such as fibrocystic diseases, sclerosing 
lesions, epithelial hyperplasia, fibroadenomas, tubular adenomas as well as intraduct 
papillomas (Courtillot et al., 2005; Bateman, 2010). Generally, these types of lesions 
are non-detrimental but have the potential to develop into breast carcinoma in situ. 
Carcinoma in situ is a pre-malignant proliferation of the breast epithelial cells 
confined within the basement membrane (Thompson et al., 2000; Russo and Russo, 
2000). It can be classified as Ductal Carcinoma In Situ (DCIS) (Figure 1.3 (B)) 
which is originated from the ductal region or Lobular Carcinoma In Situ (LCIS) from 
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the lobular region (Meijnen et al., 2006; Pinder, 2010). DCIS is exhibited in several 
histological subtypes including cribriform, comedo, solid and micropapillary whilst 
LCIS does not possess one (Mallon et al., 2000; Guinebretiere et al., 2005). In 
addition, both carcinomas in situ are known to be the precursor of invasive 
carcinoma (Polyak, 2001; Hanby, 2005). Invasive carcinoma retained similar 
characteristics as their counterpart in carcinoma in situ, but the tumour cells have 
breached the basement membrane and invade into the surrounding tissue (Russo and 
Russo, 2000; Bateman, 2010). Invasive ductal carcinoma (IDC) which is the most 
common breast carcinoma in humans has been histologically classified as special-
type and Not-Otherwise Specified (NOS) type (Figure 1.3(C)). Almost 75% of breast 
carcinoma cases in human were diagnosed as IDC-NOS (Hanby, 2005; Moinfar, 
2007) as the tumour exhibits no specific characteristics. Meanwhile, the remaining 
special-type of invasive carcinoma which have distinctive characteristics such as 
tubular carcinoma, cribriform carcinoma, solid papillary carcinoma and many more, 
rarely occur in breast carcinoma cases. In the advanced stage, breast carcinoma 
commonly metastasize to a distant organ such as lungs, liver, brain, adrenal gland 
and bones through the nearest lymphatic and vascular invasion (Mallon et al., 2000; 
Hanby, 2005). Studies have indicated that the development of breast cancer has been 
attributed to numerous factors including internal such as endocrine or hormonal 
related factors as well as external such as genetic factors, early menarche, late 
pregnancy, nulliparity and lifestyle factors for examples obesity, alcohol 
consumption and reduced physical activity (Polyak, 2001; Parkin et al., 2006).  
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Figure 1.2 Cellular organizations of normal mammary gland and types of mammary 
carcinoma (Polyak, 2001) 
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Figure 1.3 Histology of normal and cancerous breast tissue. (A) Normal mammary 
duct (Guinebretiere et al., 2005), (B) Ductal Carcinoma In Situ (DCIS) (Pinder, 
2010), (C) Invasive ductal carcinoma-Not-Otherwise Specified (IDC-NOS) 
(Moinfar, 2007) 
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1.2.2.3 Breast cancer induced by N-nitroso-N-methylurea (NMU) in rat model  
In order to fully understand the mammary carcinogenesis, animal models 
notably from mammals seem to be the best option. Studies have demonstrated that 
the histopathological characteristics of mammary carcinoma developed in rat models 
had close resemblance to the one in human (Thompson and Singh, 2000; Costa et al., 
2002; Tsubura et al., 2007; Jaafar et al., 2009). There are variety of animal models 
for breast cancer study (Cardiff and Wellings, 1999; Tsubura et al., 2007; Medina, 
2008), however chemically induced carcinogen rat model has been extensively used 
in mammary carcinogenesis study for the past several decades (Thompson et al., 
1991; Macejova and Brtko, 2001; Roomi et al., 2005; Goss et al., 2011). Out of the 
various carcinogen models studied so far, NMU and DMBA are the most commonly 
used and well-characterized (Thompson et al., 2000; Russo and Russo, 2000). NMU 
is an alkylating agent (Figure 1.4) which exhibits its toxicity by transferring its 
methyl group to nucleo bases in nucleic acids and leads to mutations. These models 
offer several advantages including ease of handling, the nature of the carcinogenic 
response, the histological characteristics of the tumour induced, the simplicity of the 
tumour induction methodology and the flexibility in the experimental design 
(Thompson and Singh, 2000). Compared to DMBA, the NMU model has a number 
of superior advantages. For instance, NMU can be used to demonstrate the 
development of histologically aggressive mammary carcinoma (Thompson et al., 
2000; Liska et al., 2000), has a higher proportion of malignant to benign tumour 
compared to DMBA (Thompson, 2002) as well as appearance of more estrogen-
dependent tumour (Arafah et al., 1980; Thompson et al., 2000; Thompson, 2002; 
Rajkumar et al., 2004). There are several suggested methods and routes of 
administration for NMU-induced mammary carcinoma. Intraperitoneal injection at 
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21 days-old of female Sprague Dawley rats is the most rapid induction method 
(Thompson, 2002). Induction during this age is ideal because at this time the TEB is 
in undifferentiated form and susceptible to neoplastic transformation which is 
attributed to the carcinogen activity (Russo et al., 1983; Thompson and Singh, 2000). 
This will only occur in young or nulliporous animals, but not in multiporous animals 
where the TEB is absent due to complete differentiation of the gland (Russo et al., 
1983). In vivo studies in rats have proven that nulliporous rat is associated with 
higher risk of developing breast cancer compared to multiporous rat (Thompson et 
al., 2000; Macejova and Brtko, 2001). Besides the TEB region, studies also indicated 
another two in vivo origin sites of mammary carcinoma which comprised of ducts 
and ductules (Russo et al., 1982). In humans, the similar pattern was observed with 
predominant human breast carcinoma originating from ductals (Thompson and 
Singh, 2000; Thompson et al., 2000; Russo and Russo, 2000; Liska et al., 2000).  
 
(Thompson et al., 2000) 
Figure 1.4 The chemical structure of NMU 
1.2.3 Angiogenesis  
Development and progression of tumour has been associated with a wide 
range of factors with tumour angiogenesis being identified as one of the factors 
(Hanahan and Weinberg, 2000; Bluff et al., 2008). In 1960, Folkman and co-workers 
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initially discovered the role of angiogenesis in supporting the tumour growth 
(Folkman, 1995; Fan et al., 1995). Angiogenesis, which refers to the formation of 
new capillaries from the pre-existing vessels is important for both physiological and 
pathological processes (Papetti and Herman, 2002; Otrock et al., 2007). In normal 
physiology, angiogenesis is a highly ordered process under tight regulation of 
angiogenic factors and inhibitors known as pro- and anti-angiogenic molecules, 
respectively (Papetti and Herman, 2002; Gasparini et al., 2005; Shojaei and Ferrara, 
2008). Pro-angiogenic molecules promote vasculature formation; whereas anti-
angiogenic molecules do the opposite (Sato, 2003; Hillen and Griffioen, 2007). The 
amount of pro-angiogenic molecules is exquisitely counterbalanced by those of anti-
angiogenic molecules to compel changes in tissue mass and/or metabolic demands in 
order to maintain adequate oxygen and nutrient delivery (Milkiewicz et al., 2006; 
Harper and Moses, 2006). This process is important during embryonic development 
where angiogenesis provides adequate vasculature for growing and developing 
organs, as well as physiological repair process in wound healing, mammary gland 
maturation and ovarian cycle during adult phase (Kliche and Waltenberger, 2001; 
Papetti and Herman, 2002; Sato, 2003). However, deregulated angiogenesis by 
overexpression or downregulation of angiogenic factors and inhibitors caused 
aberrant deployment of normal angiogenesis and resulted in various pathological 
conditions including vascular insufficiency (cerebral ischemia and myocardial 
infarction), atherosclerosis, diabetic retinopathy, psoriasis, rheumatoid arthritis and 
tumour growth as well as metastasis (Milkiewicz et al., 2006; Hillen and Griffioen, 
2007). In the case of tumour progression, absence of angiogenesis is severely 
restricting the tumour to grow beyond 1-2 mm3 (Folkman, 1995; Gasparini et al., 
2005). Moreover, angiogenesis also facilitates local invasion and metastasis as the 
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tissue oxygen diffusion is limited within 100-200 μm, which corresponds to 3–5 cell 
layers around a blood vessel (Locopo et al., 1998; Gasparini et al., 2005).  
 
1.2.3.1 Regulation of tumour angiogenesis in breast cancer  
Breast cancer has been identified as angiogenesis-dependent tumour for past 
several decades (Atiqur Rahman and Toi, 2003; Fox et al., 2007; Marty and Pivot, 
2008). Despite angiogenic factors and inhibitors, there are also other stimuli which 
have been noted to regulate breast tumour angiogenesis in direct or indirect manners 
including soluble growth factors, membrane-bound proteins, cell-matrix and cell-cell 
interactions (Papetti and Herman, 2002; Otrock et al., 2007), hypoxia (Boudreau and 
Myers, 2003), inflammation, mechanical factors (shear stress and stretch) 
(Milkiewicz et al., 2006) and oxidative as well as glucose deprivation (Gasparini et 
al., 2005). Other than that, accumulated clinical and experimental data have also 
indicated that tumour neovascularisation elicits signalling either via angiogenic 
mechanisms (i.e. sprouting angiogenesis and lymphangiogenesis) (Otrock et al., 
2007b; Lohela et al., 2009) or non-angiogenic mechanisms (i.e. intussusceptive 
angiogenesis, recruitment of endothelial progenitor cells, vessel co-option and 
vasculogenic mimicry) (Cebe-Suarez et al., 2006; Hillen and Griffioen, 2007). In this 
regard, sprouting angiogenesis or commonly known as angiogenesis has been 
described as the prominent signalling pathway in breast tumour neovascularisation 
(Hillen and Griffioen, 2007; Fox et al., 2007). Thus, further details will mainly 
emphasize more on tumour-induced sprouting angiogenesis instead of the remaining 
mechanisms.  
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1.2.3.1.1 Vascular endothelial Growth Factor Receptor (VEGFR) 
Basically, the tumour angiogenesis process involves two general phases 
which begins with prevascular phase (non-angiogenic phenotype), often found in 
benign tumours, and subsequently switching to vascular phase (angiogenic 
phenotype), frequently found in malignant tumours (Folkman, 1995; Shinkaruk et 
al., 2003; Cross et al., 2003). Transformation from avascular to vascular phase will 
only occur when overwhelming production of pro-angiogenic factors particularly 
Vascular Endothelial Growth Factor (VEGF) secretes from the tumour cells (Hicklin 
and Ellis, 2005; Fox et al., 2007). For decades, researchers have implicated that 
VEGF and its cognate receptors are regularly over expressed in a diverse range of 
human cancers notably in breast cancer (Atiqur Rahman and Toi, 2003; Salter and 
Miller, 2007; Schneider and Sledge, 2007). VEGF is the prime pro-angiogenic factor 
that prominently regulated during tumour angiogenesis development and progression 
(Miller, 2004; Salter and Miller, 2007; Zelnak and O’Regan, 2007). It exists in 
multiple isoforms which have distinct physical and biological properties (Tammela et 
al., 2005; Lohela et al., 2009). VEGFs elicit their angiogenic responses via three 
specific tyrosine kinase receptors known as: VEGFR-1 (also referred as fms-like 
tyrosine kinase 1 (Flt-1)), VEGFR-2 (also known as kinase insert domain-containing 
receptor (KDR) or its murine homolog, fetal liver kinase 1 (Flk-1)) and VEGFR-3 
(also known as fms-like tyrosine kinase 4 (Flt-4)) (Takahashi and Shibuya, 2005; 
Veeravagu et al., 2007). VEGFR-1 and VEGFR-2 are cell surface receptors which 
were initially discovered on endothelial cells and characterized as specific receptor 
tyrosine kinases (RTK) (Hicklin and Ellis, 2005). As depicted in Figure 1.5, both 
receptors share 45% homology sequences and possess similar organizational 
structure composed of seven immunoglobulin-like domains in the extracellular 
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domain, a single hydrophobic trans-membrane domain, and an intracellular 
cytoplasmic domain with tyrosine-kinase activity essential for signal transduction 
(Shinkaruk et al., 2003; Hicklin and Ellis, 2005; Cebe-Suarez et al., 2006; Lohela et 
al., 2009). Each receptor was distinguished by a short interrupted sequence with 80% 
similarity of tyrosine kinase domain (Shinkaruk et al., 2003) 
Vascular endothelial growth factors (VEGFs) are crucial regulators of 
vascular development during embryogenesis (vasculogenesis) as well as blood-vessel 
formation (angiogenesis) in adults. In mammals, five VEGF ligands, which occur in 
several different splice variants and processed forms, have been identified so far 
(Folkman, 1995; Shinkaruk et al., 2003; Cross et al., 2003). These ligands bind in an 
overlapping pattern to three receptor tyrosine kinases (RTKs), known as VEGF 
receptor-1, -2 and -3 (VEGFR1–3), as well as to co-receptors (defined as VEGF-
binding molecules that lack established VEGF-induced catalytic function), such as 
heparan sulphate proteoglycans (HSPGs) and neuropilins (Takahashi and Shibuya, 
2005; Veeravagu et al., 2007). In certain respects, VEGFs share regulatory 
mechanisms with other well-characterized RTKs, such as the platelet-derived 
growth-factor receptors (PDGFRs) and the epidermal growth-factor receptors 
(EGFRs) (Hicklin and Ellis, 2005). These mechanisms include receptor dimerization 
and activation of the tyrosine kinase, as well as creation of docking sites for signal 
transducers. Moreover, the VEGFRs induce cellular processes that are common to 
many growth-factor receptors, including cell migration, survival and proliferation. 
However, the VEGFRs also seem to be unique, for example, in their ability to 
transduce signals that form the three-dimensional vascular tube, and in regulating 
vascular permeability that leads to oedema and swelling of tissues. VEGFR1 is a 
positive regulator of monocyte and macrophage migration, and has been described as 
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a positive and negative regulator of VEGFR2 signalling capacity. Negative 
regulation is exerted, at least in part, by an alternatively spliced soluble VEGFR1 
variant that binds to VEGF and thereby prevents VEGF from binding to VEGFR2 
(Shinkaruk et al., 2003; Hicklin and Ellis, 2005; Cebe-Suarez et al., 2006; Lohela et 
al., 2009). VEGFR2 is implicated in all aspects of normal and pathological vascular-
endothelial-cell biology, whereas VEGFR3 is important for lymphatic endothelial 
cell development and function. Recently, tumour therapies that are based on 
neutralizing anti-VEGF antibodies and small-molecular-weight tyrosine-kinase 
inhibitors that target the VEGFRs have been developed. These new strategies for 
tumour treatment show the clinical relevance of inhibiting VEGF signal-transduction 
pathways that are exaggerated in pathological angiogenesis.  
 
 
Figure 1.5 Schematic diagrams of VEGF family ligands and their respective 
receptors (Hicklin and Ellis, 2005) 
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1.2.3.1.1.1 Flt-1  
Vascular endothelial growth factor receptor 1 is a protein that encoded by 
the Flt-1 gene. In human, the functional relevance of Flt-1 has been subjected of 
intense debate. Flt-1 binds to VEGF, PlGF, and VEGF-B with at least 10-fold higher 
affinity than Flk-1 binds to VEGF (Shibuya, 2001). However, Flt-1 has a weaker 
tyrosine kinase activity (Park et al., 1994), and has been proposed to act as a decoy, 
regulating the availability of VEGF (Hiratsuka et al., 1998). Other studies indicated, 
however, that Flt-1 interacts with various signal transducing proteins and generates 
signals (Luttun et al., 2002; Autiero et al., 2003). The precise role of VEGF-B and 
Flt-1 in the nervous system is still unclear. Flt-1 is upregulated in astrocytes after 
administration of VEGF (Mani et al., 2005) or after injury (Choi et al., 2007), and 
stimulates migration of microglial cells in vitro (Forstreuter et al., 2002). Loss of 
VEGF-B promote stroke, whereas VEGF-B stimulates proliferation of neuronal 
cultures in vitro (Sun et al., 2004) and neurogenesis in vivo (Sun et al., 2006), and is 
protective in injury models, such as axotomy- and NMDA-induced cell death in the 
retina (Li et al., 2008). VEGF-B has been presumed to exert direct neuroprotective 
effects, but this evidence was based on anti-apoptotic effects on smooth muscle cells 
and retinal pericyte cell lines (Li et al., 2008). However, evidence that VEGF-B has 
direct neuroprotective effects on primary neurons has not yet been provided, nor has 
long-term delivery been shown to improve the disease course or outcome.  
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1.2.3.1.1.2 Flk-1 
Flk-1 is the most prominent and major mediator in tumour angiogenesis. The 
mechanism of action of Flk-1 in breast tumour is depicted in Figure 1.6. Flk-1 is a 
strong ligand-dependent tyrosine phosphorylation (Otrock et al., 2007). Secretion of 
VEGF from the luminal surface of the vascular endothelium (i.e. circulating cells), or 
from the abluminal surface (i.e. pericytes, stromal cells and tumour cells) can initiate 
the signalling once it binds to the extracellular domain of Flk-1 (Weis and Cheresh, 
2005). Once the Flk-1 undergoes dimerization and autophosphorylation of the 
intracellular domain, a cascade of downstream proteins will be activated that will 
further regulates the endothelial cell proliferation, migration, survival, vascular 
permeability and dilation (Cross et al., 2003; Hicklin and Ellis, 2005) as well as cell 
differentiation (Cebe-Suarez et al., 2006). Different cascades will be activated 
pertaining to different tyrosine-phosphorylation sites (Rahimi, 2006). Currently, 
there are seven well-described putative tyrosine-phosphorylation sites of Flk-1 from 
a total of 19 tyrosine residues present in the intracellular domain (Cebe-Suarez et al., 
2006). The phosphorylation sites are constructed out of the kinase insert domain 
(Tyr951 and Tyr996), the kinase domain (Tyr1054 and Tyr1059) (Zachary and Gliki, 
2001), the C-terminal tail (Tyr1175 and Tyr1214) (Cross et al., 2003) and Tyr801 
(Cebe-Suarez et al., 2006). Phosphorylation of Tyr1175 leads to activation of 
phospholipase C- (PLC) and protein kinase C (PKC) followed by stimulation of Ras-
Raf1-MEK-ERK and results in cell proliferation (Cebe-Suarez et al., 2006; Otrock et 
al., 2007). Earlier studies demonstrated that phosphorylation of Tyr1175 also 
promotes cell survival via activation of phosphoinositide 3-kinase (PI3K)-Akt/PKB 
pathway (Kliche and Waltenberger, 2001; Lohela et al., 2009). The Akt/PKB 
pathway also induces vascular permeability via activation of endothelial nitric oxide 
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synthase (eNOS) (Cross et al., 2003; Lohela et al., 2009). In addition, Flk-1 regulates 
cell migration through several different pathways including Tyr951-TSAd (T-cell-
specific adaptor) and p38 MAPK (mitogen-activated protein kinase)-HSP27 (heat-
shock protein-27) pathway as well as focal adhesion kinase (FAK) and its substrate, 
paxilin pathway (Olsson et al., 2006). 
 
 
Figure 1.6 Regulation of VEGF signalling pathway (Olsson et al., 2006). 
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1.2.3.1.1.3 Flt-4 
Flt-4 is a third receptor for a ligand of the VEGF family, VEGF-C (Joukov et 
al., 1996). It’s expression in adult mice appears predominant in the endothelial cells 
of lymphatic vessels (Kaipanen et al., 1995). The human Flt-4 locus encodes two 
isoforms. The long form, Flt-4L, differs from the short form, Flt-4S, by the addition 
of 65 amino acids in the C-terminal region (Pajusola et al., 1993, Fournier et 
al., 1995).  Another member of the VEGF family, VEGF-C, was isolated as a ligand 
for the tyrosine kinase VEGFR-3 (Flt4) (Fong et al., 1995), a receptor that is 
expressed in endothelial cell precursors in 8.5 days mouse embryos and later in 
development is expressed in venous and lymphatic endothelium (De Vries et al., 
1992). The pattern of VEGF-C gene expression in mouse embryos suggests that 
VEGF-C may regulate angiogenesis of the lymphatic vasculature (Terman et al., 
1992). VEGF-C is also a ligand for Flk-1 (Fong et al., 1995), but the functional 
significance of this potential interaction in vivo is unknown. The amino acid 
sequence of VEGF-C has a central region that is related to other members of the 
VEGF family and exhibits approximately 30% identity to VEGF. In addition, the 
VEGF-C sequence has N-terminal and C-terminal extensions that are not present in 
VEGF, PlGF, or VEGF-B (Fong et al., 1995, Quinn et al., 1993). The biosynthesis of 
VEGF-C involves proteolytic processing that gives rise to a mature secreted protein 
that essentially consists of the VEGF homology domain (Park et al., 1994), i.e., the 
portion of the molecule that is related in primary structure to all other members of the 
VEGF family and that contains the cystine knot motif that is found in VEGF family 
members and in other growth factors (Waltenberger et al., 1994). 
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1.2.3.2 Angiogenic inhibitors  
The role of tumour angiogenesis in supporting the tumour development and 
progression has been well understood. Thus, targeting the tumour angiogenesis 
seems to be a potential strategy in treating the solid tumour like breast cancer.  
 
1.2.3.2.1 Rapamycin  
Rapamycin was first identified as an anti-fungal agent isolated from 
bacterium Streptomyces hygroscopicus at Easter Island (Rapa Nui) in 1975 (Noh et 
al., 2004; Koehl et al., 2005). Later, it was introduced as a potent 
immunosuppressant agent and has been applied clinically for treatment in organ 
transplantation (Sehgal, 1998; Gaumann et al., 2008). However, one of the 
shortcomings in organ transplant patients is the development of tumour occurrence 
(Kauffman et al., 2006; Leblanc et al., 2011; Schnitzbauer et al., 2011). Previous 
studies demonstrated that cyclosporine; the most widely used immunosuppressive 
drug promotes tumour development, whilst immunosuppressant dosage of rapamycin 
simultaneously inhibits tumour occurrence (Luan et al., 2002).  
Since then, various researches have been conducted to determine the anti-
tumour properties of rapamycin and findings have ruled out that rapamycin inhibits 
tumour growth by halting tumour cell proliferation, inducing tumour cell apoptosis, 
and suppressing tumour angiogenesis (Guba et al., 2002; Law, 2005; Gaumann et al., 
2008). One study suggested that rapamycin inhibits development of highly invasive 
and metastatic mammary tumour (Met-1) in vivo via suppression of p70S6K and 4E-
BP1 which are known as downstream effectors of mTOR signalling cascade (Namba 
et al., 2006). It is well known that activation of PI3K-PDK1-Akt phosporylates 
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downstream effectors of mTOR, p70S6 kinase and 4E-BP1, and leads to tumour cell 
proliferation (Law, 2005). Koehl et al., (2005) reported that rapamycin inhibits 
tumour cell proliferation via disruption of receptors which serves as docking site for 
p70S6 kinase and 4E-BP1. In addition, rapamycin also act as a pro-survival by 
inhibiting cyclin dependent kinase 1 (CDK1) which leads to cell cycle arrest at G1 
phase in T lymphocytes, suppression of Cyclin D1, D3, A and c-Myc as well as 
promoting tumour cell apoptosis (Koehl et al., 2005; Law, 2005). Recently, 
increasing body of evidence implicated that rapamycin exerts anti-angiogenic 
properties by suppressing VEGF expression in several in vitro and in vivo tumour 
models (Guba et al., 2002; Stephan et al., 2004; Molhoek et al., 2008).  
 
(Foster et al., 2010) 
Figure 1.7 The chemical structure of rapamycin 
 
1.2.3.2.2 Platelet Factor 4 (PF4)  
Platelet Factor 4 (PF4) is one of the angiostatic member of the chemokine 
family also recognized as CXCL4 (chemokine ligand 4) according to the new 
nomenclature of chemokines (Strieter et al., 2004). It was first discovered in 1977 as 
